Research Study

A Pilot Study to Determine if Pantoprazole Modifies Steady-State Plasma Concentrations of Orally Administered Psychotropic Medications
Principal Investigator 
Ric Procyshyn

Overview

Body Locations and Systems 
Brain
Disorders and Conditions 
Mental Health
ClinicalTrials.gov# 
NCT02213887
Status 
Closed for Recruitment
Study Start/End 
Sep 1, 2014 to Mar 21, 2017
Locations 
St. Paul's Hospital, UBC Hospital
Name/Title 
Heidi Boyda, Post Doctoral Fellow
Phone 
604-822-7500
Email Address 
hnboyda@gmail.com
Purpose of Study 

The purpose of this 9-day study is to determine if:

  • Pantoprazole modifies the steady-state plasma concentrations of orally administered psychotropic medications including valproic acid, lithium, and second-generation antipsychotics (i.e., aripiprazole, asenapine, clozapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone)
  • Serum gastrin levels change within a week of starting or stopping pantoprazole
Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.